Phase 1 clinical trials of a COVID-19 vaccine are set to begin this month in Melbourne and Brisbane with preliminary results expected in July.
The vaccine candidate, Recombinant Spike Protein Nanoparticle vaccine, NVX-CoV2373, uses just part of the virus – the spike protein – to create antibodies, and has reportedly already shown success in animal models.
Australian researcher Nucleus Network is holding the trials at its two clinics in Melbourne and Brisbane in collaboration with US biotech company Novavax.
Novavax has received $US388 million from the Coalition for Epidemic Preparedness (CEPI) to fund the trial, and to scale up manufacturing capacity.
>> Read the original article here
Source: Forbes
